1312608-46-0

Basic information

• Product Name: C₄₁H₅₀N₈O₈
• Synonyms: C₄₁H₅₀N₈O₈
• CAS NO: 1312608-46-0
• Molecular Weight: 782.897
• Mol File: 1312608-46-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: C₄₁H₅₀N₈O₈(CAS DataBase Reference)
• NIST Chemistry Reference: C₄₁H₅₀N₈O₈(1312608-46-0)
• EPA Substance Registry System: C₄₁H₅₀N₈O₈(1312608-46-0)

Safety Data

• Hazardous Substances Data: 1312608-46-0(Hazardous Substances Data)

Upstream product

• 111398-44-8 N-methoxycarbonyl-L-valine 
• 1007882-12-3 (S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1312610-12-0 C₄₁H₅₀N₄O₁₄ 
• 1312610-11-9 C₁₇H₁₂Br₂O₄ 
• 1312610-10-8 C₁₅H₈Cl₂O₄ 
• 1312610-09-5 C₁₅H₁₀O₆ 
• 1312610-08-4 C₁₈H₁₆O₆ 
• 1312610-07-3 C₁₀H₉BrO₄ 
• 1312609-83-8 4-bromo-2,3-dihydroxybenzoic acid ethyl ester 
• 61203-52-9 4-bromo-2,3-dihydroxybenzoic acid 
• 72517-19-2 2,3-dihydroxy-4-nitrobenzoic acid 
• 7150-01-8 2-acetoxy-3-methoxybenzaldehyde 
• 148-53-8 3-methoxy-2-hydroxybenzaldehyde 

Relevant articles and documents

HIGHLY ACTIVE DRUG COMBINATION FOR TREATMENT OF HEPATITIS C VIRUS

A combination is provided of Compound 1 or a pharmaceutically acceptable salt thereof (such as Compound 1-A) and Compound 2 or a pharmaceutically acceptable salt thereof (such as Compound 2-A) to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms thereof.

NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formulae I, II, III, IV, or V as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.